Zoledronic acid in the treatment of osteoporosis: indications for use

The mechanism of action of the third-generation bisphosphonate zoledronic acid (Aclasta) is described; the data of randomized clinical trials of its efficacy and tolerability are given. It is concluded that zoledronic acid intravenously administered once a year may be the drug of choice for increasing patients' adherence to therapy, particularly in polypharmacy that is common in the elderly and in cognitive disorders. In addition, the drug may be given to postmenopausal women once every 2 years for the prevention of osteoporosis